Table 2. Relationships of FEN1 and RAD54B expression with clinical parameters in lung adenocarcinoma patients.
| FEN1 | RAD54B | ||||||
|---|---|---|---|---|---|---|---|
| Parameters | Case number | 0 | 1–2 | p value | 0 | 1–2 | p value |
| Age(SD), year | 93 | 64.4 (11.6) | 64.3 (13.5) | 0.9701 | 65.5 (11.0) | 62.5 (14.6) | 0.2735 |
| Gender, n(%) | |||||||
| Female | 50 (53.8) | 24 (50.0) | 26 (42.2) | 28 (48.3) | 15 (42.9) | ||
| Male | 43 (46.20 | 24 (50.0) | 19 (57.8) | 0.4522 | 30 (51.7) | 20 (57.1) | 0.6116 |
| Stage, n(%) | |||||||
| I | 36 (38.7) | 20 (41.7) | 16 (35.6) | 24 (41.4) | 12 (34.3) | ||
| II | 11 (11.8) | 3 (6.3) | 8 (17.8) | 8 (13.8) | 3 (8.6) | ||
| III | 23 (24.7) | 12 (25.0) | 11 (24.4) | 14 (24.1) | 9 (25.7) | ||
| IV | 23 (24.7) | 13 (27.1) | 10 (22.2) | 0.3827 | 12 (20.7) | 11 (31.4) | 0.6091 |
| T value, n(%) | |||||||
| 1 | 37 (39.8) | 22 (45.8) | 15 (33.3) | 28 (48.3) | 9 (25.7) | ||
| 2 | 39 (41.9) | 16 (33.3) | 23 (51.1) | 20 (34.5) | 19 (54.3) | ||
| 3 | 12 (12.9) | 7 (14.6) | 5 (11.1) | 7 (12.1) | 5 (14.3) | ||
| 4 | 5 (5.4) | 3 (6.3) | 2 (4.4) | 0.3885 | 3 (5.2) | 2 (5.7) | 0.1771 |
| N value, n(%) | |||||||
| 0 | 57 (61.3) | 32 (66.7) | 25 (55.6) | 38 (65.5) | 19 (54.3) | ||
| 1 | 6 (6.5) | 2 (4.2) | 4 (8.9) | 4 (6.9) | 2 (5.7) | ||
| 2 | 24 (25.8) | 12 (25.0) | 12 (26.7) | 13 (22.4) | 11 (31.4) | ||
| 3 | 6 (6.5) | 2 (4.2) | 4 (8.9) | 0.5522 | 3 (5.2) | 3 (8.6) | 0.6651 |
| M value, n(%) | |||||||
| 0 | 70 (75.3) | 36 (75.0) | 34 (75.6) | 46 (79.3) | 24 (68.6) | ||
| 1 | 23 (24.7) | 12 (25.0) | 11 (24.4) | 0.9505 | 12 (20.7) | 11 (31.4) | 0.2449 |
| CT, n(%) | |||||||
| No | 45 (48.4) | 23 (47.9) | 22 (48.9) | 30 (51.7) | 15 (42.9) | ||
| Yes | 48 (51.6) | 25 (52.1) | 23 (51.1) | 0.9253 | 28 (48.3) | 20 (57.1) | 0.4071 |
| RT, n(%) | |||||||
| No | 67 (72.0) | 33 (68.8) | 34 (75.6) | 42 (72.4) | 25 (71.4) | ||
| Yes | 26 (28.0) | 15 (31.3) | 11 (24.4) | 0.4649 | 16 (27.6) | 10 (28.6) | 0.9183 |